Suven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 17, 2026, titled "Suven Life Sciences announces Positive Topline results from Phase-2b clinical Proof-of-Concept trial of Ropanicant for the treatment of Major Depressive Disorder".
